Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid…

Overview of attention for article published in BioDrugs, June 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet

Citations

dimensions_citation: 43 Dimensions

Readers on

mendeley: 87 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 1 news story.

New data show Truxima® (CT-P10) to have comparable efficacy and tolerability in advanced follicular lymphoma to reference i.v. rituximab

Bioportfolio, 14 Jun 2017

Results of a randomized controlled trial to assess the efficacy and tolerability of Truxima® (i.v.